TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of “Buy” by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been given an average recommendation of “Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.75.

TLSI has been the topic of a number of analyst reports. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, March 28th.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, insider Richard Marshak sold 6,597 shares of the firm’s stock in a transaction on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the sale, the insider now owns 69,101 shares of the company’s stock, valued at approximately $357,943.18. This trade represents a 8.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 16,125 shares of company stock valued at $83,528. 27.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in shares of TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after acquiring an additional 178,298 shares during the last quarter. Northern Trust Corp lifted its stake in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after acquiring an additional 5,936 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of TriSalus Life Sciences in the 4th quarter valued at $67,000. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after acquiring an additional 3,710 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after acquiring an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Trading Up 4.8%

TriSalus Life Sciences stock opened at $5.50 on Friday. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $6.18. The stock’s 50 day moving average is $5.41 and its 200-day moving average is $5.16. The company has a market capitalization of $208.11 million, a price-to-earnings ratio of -2.21 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the prior year, the company earned ($0.60) earnings per share. As a group, equities research analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.